Premium
Pharmacological evaluation of an analogue of L‐carnitine in obese Zucker‐Lepr fa/fa rats
Author(s) -
Rodríguez-Fragoso Lourdes,
Mendoza Brissa,
De la Cruz Cordero Ricardo,
Vite Odon,
Avalos-Soriano Anaguiven,
Esparza Jorge Reyes
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.570.1
Subject(s) - carnitine , endocrinology , dyslipidemia , medicine , triglyceride , diabetes mellitus , glycogen , overweight , population , obesity , metabolic syndrome , potency , chemistry , cholesterol , biochemistry , in vitro , environmental health
Different diseases such Diabetes mellitus type 2, hypertension, dyslipidemia, among others, are attributed to overweight and obesity, which have become a major health problem worldwide and turn all these factors are the main components of metabolic syndrome (MS). Molecules like L‐carnitine has been shown to be effective in treating a variety of related diseases with SM. Result obtained of this molecule has led to the search for the synthesis of new analogues of L‐carnitine to have new treatment options. Therefore aim of this research was to evaluate the pharmacological effect of different doses of an analogue of L‐carnitine on parameters related to metabolic syndrome in Zucker rats. Animals treated for 5 weeks with L‐carnitine and the doses used were 100 and 250 mg / kg. The results showed that the analogue of L‐carnitine at doses of 100 mg / kg led to the decrease in hepatic glucose, serum triglycerides and liver, hepatic cholesterol and increased liver glycogen levels, populations changed peripheral blood lymphocytes and CD3/CD8 increasing CD3/CD4, CD3 thymus decreased and increased CD3/CD4/CD8 of this population. With doses of 250 mg / kg, only decreased serum triglyceride levels and increased liver glycogen levels, among others effects. In conclusion, the results obtained in this project showed that the analogue of L‐carnitine increased efficacy and potency at a dose of 100 mg / kg. Support from CONACYT 153324.